source
- FDA's PDUFA VIII adds 'America First' incentives and speeds up drug reviewsThe Food and Drug Administration announced the next five‑year reauthorization of the Prescription Drug User Fee Act, known as PDUFA VIII. The agency said the new framework will introduce several po…
- PTC Therapeutics agrees to pay up to $211 million for Sangamo’s experimental Fabry disease gene therapyPTC Therapeutics announced it will invest up to $211 million to acquire rights to an advanced gene therapy for Fabry disease being developed by Sangamo Therapeutics. The therapy, called ST-920 (is…